Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The field of regenerative medicine is becoming an exciting area in both human and veterinary medicine that may greatly impact our ability to treat patients. Two main tools extensively being investigated are platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs) and how they may aid in the treatment of orthopedic diseases. The PRP is plasma with a greater concentration of platelets than that found in whole blood, and rationale for its use arises from the release of growth factors, including platelet-derived growth factor (PDGF), transforming growth factor beta (TGFβ), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and insulin-like growth factors 1 and 2 (IGF), and other cytokines, including interleukin 8. These molecules are released from the alpha granules when platelets rupture or lyse. This process is also referred to as activation of PRP and it is these growth factors and cytokines that locally induce endogenous bone and soft tissue regeneration. Plateletrich- plasma also offers a significant advantage over other potential cell-based therapies in that it is autologous (i.e. the donor and the patient are the same), and hence, avoiding graft vs. host complications.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi